The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| RVTY | -26.58% | -35.02% | -8.25% | +5,630% |
| S&P | +12.65% | +91.73% | +13.89% | +6,901% |
Revvity, Inc. engages in the provision of products, services, and solutions for diagnostics, food, environmental, life sciences, and applied markets. It operates through the following segments: Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment consists of technologies that help life sciences researchers better understand diseases and develop treatments. The Diagnostics segment offers instruments, reagents, assay platforms, and software to hospitals, medical labs, clinicians, and medical research professionals to help improve the health of families. The company was founded by Richard Scott Perkin and Charles W. Elmer on April 19, 1937, and is headquartered in Waltham, MA.
Revvity announced disappointing results and lowered its full-year outlook. Here's what investors need to know.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $698.95M | 2.2% |
| Gross Profit | $325.90M | -15.3% |
| Gross Margin | 46.63% | -9.6% |
| Market Cap | $10.17B | -35.4% |
| Market Cap / Employee | $0.92M | 0.0% |
| Employees | 11K | -4.3% |
| Net Income | $47.22M | -49.4% |
| EBITDA | $192.92M | -8.3% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $932.58M | -24.2% |
| Accounts Receivable | $680.26M | 13.0% |
| Inventory | 379.9 | -6.1% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $2.79B | -16.0% |
| Short Term Debt | $583.84M | 55770.2% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 1.87% | -0.1% |
| Return On Invested Capital | 5.81% | -0.4% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $120.00M | -4.4% |
| Operating Free Cash Flow | $138.50M | -6.3% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Earnings | 46.49 | 41.76 | 41.51 | 42.04 | -17.93% |
| Price to Book | 1.72 | 1.66 | 1.51 | 1.35 | -32.61% |
| Price to Sales | 4.95 | 4.58 | 4.11 | 3.45 | -39.46% |
| Price to Tangible Book Value | -9.73 | -8.88 | -7.99 | -6.48 | -40.28% |
| Price to Free Cash Flow TTM | 26.90 | 26.05 | 24.64 | 21.03 | -28.16% |
| Enterprise Value to EBITDA | 66.60 | 80.29 | 66.87 | 62.94 | -24.78% |
| Free Cash Flow Yield | 3.7% | 3.8% | 4.1% | 4.8% | 39.20% |
| Return on Equity | 3.6% | 3.8% | 3.6% | 3.0% | -8.10% |
| Total Debt | $3.33B | $3.33B | $3.37B | $3.37B | 1.62% |
No podcast episodes available.
PKI earnings call for the period ending October 30, 2021.
PKI earnings call for the period ending June 30, 2021.
PKI earnings call for the period ending March 31, 2021.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
